NCT07088263 2025-12-11
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
Sun Yat-sen University
Phase 3 Recruiting
Clinical Trials
7 trialsNCT03264547 2025-09-29
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
Japan Breast Cancer Research Group
Phase 3 Completed
NCT02514681 2025-09-10
PRECIOUS
Japan Breast Cancer Research Group
Phase 3 Completed
NCT06255392 2025-08-15
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT02037529 2024-08-20
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
Academic and Community Cancer Research United
Phase 3 Suspended
NCT02344472 2024-06-04
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
Phase 3 Active not recruiting
NCT06268652 2024-02-20
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
Sun Yat-sen University
Phase 3 Recruiting